IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57

Rhea-AI Filing Summary

IDEAYA Biosciences director Terry J. Rosen received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. According to the footnote, 100% of the option vests on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he continues serving on the Board until that vesting date.

Insights

Equity Compensation Analyst

Routine director option grant of 20,000 shares at $30.57.

IDEAYA Biosciences granted director Terry J. Rosen stock options over 20,000 common shares at an exercise price of $30.57. The filing characterizes this as a grant or award, indicating compensation rather than a market purchase.

The options vest fully on the earlier of the first anniversary of the grant or immediately before the next Annual Meeting, contingent on continued Board service. This structure aligns director incentives with shareholder outcomes over roughly a one-year horizon.

The Form 4 shows 20,000 derivative securities held following the transaction, with no simultaneous sales or exercises disclosed. As a standard equity compensation grant, it does not materially change the broader investment thesis on its own.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ROSEN TERRY J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 20,000 options Exercise price: $30.57 per share Expiration date: June 16, 2036 +2 more

5 metrics

Option grant size 20,000 options Stock Option (right to buy) granted to director

Exercise price $30.57 per share Conversion/exercise price of granted options

Expiration date June 16, 2036 Option term for the 20,000-share grant

Underlying shares 20,000 shares Common stock underlying the options

Post-transaction derivative holdings 20,000 options Total derivative securities following this grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, derivative securities, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 30.5700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount: 1 derivative-type record"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"100% of the shares subject to the option shall vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSEN TERRY J

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$30.57	06/16/2026		A		20,000		(1)	06/16/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

	/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Terry J. Rosen	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IDEAYA Biosciences (IDYA) director Terry J. Rosen report on this Form 4?

Terry J. Rosen reported receiving a grant of stock options for 20,000 shares of IDEAYA Biosciences common stock. The options were awarded as compensation and are classified as a derivative security, not as an open-market stock purchase or sale.

What is the exercise price and expiration date of the new IDEAYA (IDYA) stock options?

The granted stock options have an exercise price of $30.57 per share and expire on June 16, 2036. This means Rosen can choose to buy up to 20,000 shares at $30.57 any time before that expiration date, once vested.

How do the Terry J. Rosen IDEAYA (IDYA) options vest?

The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting. Vesting is conditional on Rosen continuing to serve on the Board through the applicable vesting date, aligning his incentives with ongoing Board service.

Did Terry J. Rosen buy or sell IDEAYA (IDYA) shares in the market in this Form 4?

No open-market buys or sells are reported. The Form 4 shows a grant of stock options classified as a “Grant, award, or other acquisition,” with no corresponding sale transactions, so this reflects compensation rather than trading activity in IDEAYA common shares.

How many IDEAYA (IDYA) derivative securities does Terry J. Rosen hold after this transaction?

Following the reported grant, Rosen holds 20,000 stock options as derivative securities according to the filing. These options each relate to one share of common stock and are exercisable at $30.57 per share until their expiration on June 16, 2036.